Amgen Strengthens Rare Disease Portfolio with New EULAR 2026 Data
Event summary
- Amgen presented new data on UPLIZNA® (inebilizumab) and TAVNEOS® (avacopan) at EULAR 2026, highlighting long-term safety and efficacy in rare autoimmune diseases.
- Phase 3 MITIGATE trial data showed 71.4% of IgG4-RD patients achieved flare-free, glucocorticoid-free complete remission with UPLIZNA after one year.
- Real-world evidence supported TAVNEOS's efficacy in reducing steroid use in ANCA-associated vasculitis patients.
- Amgen's presentations underscored the chronic and unpredictable nature of IgG4-RD and the need for earlier intervention.
The big picture
Amgen's data presentations at EULAR 2026 reinforce its commitment to advancing treatments for rare autoimmune diseases. The focus on long-term safety and efficacy of UPLIZNA and TAVNEOS aligns with broader industry trends toward targeted therapies and reduced reliance on steroids. The insights into disease biology and biomarker changes position Amgen to optimize treatment approaches and address significant unmet medical needs in these conditions.
What we're watching
- Long-term Efficacy
- How sustained results from UPLIZNA in IgG4-RD will impact its market position and adoption rates.
- Steroid Reduction
- Whether TAVNEOS can maintain disease control with reduced steroid use, addressing long-term patient risks.
- Biomarker Research
- The pace at which biomarker insights from the MITIGATE trial will translate into earlier intervention strategies for IgG4-RD.
Related topics